Kairos Pharma, LTD. (KAPA) — Institutional Holders, Q2 2026
14 institutional investment managers reported a KAPA position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $371.1K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
KAPA in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- CITADEL ADVISORSNew · +309,834 sh+$118.9K
- Virtu FinancialNew · +82,092 sh+$31.5K
- JANE STREET GROUPNew · +33,749 sh+$12.9K
- SUSQUEHANNA INTERNATIONAL GROUP, LLPNew · +29,292 sh+$11.2K
- XTX Topco LtdNew · +14,918 sh+$5.7K
Biggest sellers
- TWO SIGMA INVESTMENTSSold out · -39,543 sh-$15.2K
- GEODE CAPITAL MANAGEMENTTrimmed · -32,366 sh-$12.4K
- HRT FINANCIALSold out · -21,575 sh-$8.3K
- TWO SIGMA SECURITIESSold out · -16,247 sh-$6.2K
- Tower Research Capital (TRC)Trimmed · -229 sh-$88.00
KAPA 13F holders ranked 1–14 of 14
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS#1 · 309,834 sh | 309,834 | $118.9K | 0.00% | New |
| 2 | VANGUARD CAPITAL MANAGEMENT#2 · 231,878 sh | 231,878 | $89.0K | 0.00% | 0.0% |
| 3 | Virtu Financial#3 · 82,092 sh | 82,092 | $31.0K | <0.01% | New |
| 4 | GEODE CAPITAL MANAGEMENT#4 · 78,924 sh | 78,924 | $30.3K | 0.00% | -29.1% |
| 5 | VANGUARD FIDUCIARY#5 · 63,884 sh | 63,884 | $24.5K | 0.00% | 0.0% |
| 6 | SevenBridge Financial Group#6 · 44,286 sh | 44,286 | $17.1K | — | 0.0% |
| 7 | Aptus Capital Advisors#7 · 44,286 sh | 44,286 | $17.0K | <0.01% | 0.0% |
| 8 | JANE STREET GROUP#8 · 33,749 sh | 33,749 | $12.9K | 0.00% | New |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP#9 · 29,292 sh | 29,292 | $11.2K | 0.00% | New |
| 10 | STATE STREET#10 · 24,100 sh | 24,100 | $9.2K | 0.00% | 0.0% |
| 11 | XTX Topco Ltd#11 · 14,918 sh | 14,918 | $5.7K | <0.01% | New |
| 12 | UBS Group AG#12 · 6,261 sh | 6,261 | $2.4K | 0.00% | New |
| 13 | Tower Research Capital (TRC)#13 · 3,733 sh | 3,733 | $1.4K | 0.00% | -5.8% |
| 14 | BARCLAYS PLC#14 · 723 sh | 723 | $277.00 | 0.00% | New |
Funds that sold out of KAPA in Q2 2026 (4)
Held KAPA at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| TWO SIGMA INVESTMENTS39,543 sh | 39,543 | $22.1K |
| HRT FINANCIAL21,575 sh | 21,575 | $12.0K |
| TWO SIGMA SECURITIES16,247 sh | 16,247 | $9.1K |
| CITIGROUP10 sh | 10 | $6.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.